Literature DB >> 2298269

Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis.

I C Slaper-Cortenbach1, L G Admiraal, E F van Leeuwen, J M Kerr, A E von dem Borne, P A Tetteroo.   

Abstract

The effectiveness of a simple immunorosette technique for the depletion of common acute lymphatic leukemic (cALL) blasts from autologous bone marrow transplants was studied. Erythrocytes were sensitized with tetramolecular complexes consisting of rat anti-mouse IgG1 monoclonal antibodies (McAbs) that crosslink two different mouse McAbs. One of the McAbs was directed against glycophorin A, and the other was directed against marker glycoproteins of B cells and their precursors (CD9, CD10, CD19, or CD22). Immunorosettes were formed by addition of the sensitized erythrocytes to the cALL+ cells. After density-gradient separation of immunorosettes from mixtures of cALL+/terminal deoxynucleotidyl transferase-positive (TdT+) leukemic blasts and mononuclear bone marrow cells, nearly a 2-log depletion of leukemic cells was measured by flow cytometry. Clonogenic assays with two cALL+B-cell lines (Ros-17 and Nalm-16) were performed to compare the efficacy of complement-mediated cell lysis, immunorosette depletion, and a combination of both procedures. Complement-mediated cytotoxicity with the three McAbs in combination with baby rabbit complement yielded a 1- to 2-log cell kill. Immunorosette depletion resulted in a 3-log reduction of clonogenic units. Sequential application of the two methods (immunorosette depletion with CD19 McAb followed by a complement lysis with CD9 and CD10 McAbs) led to superior results in causing a 4- to 5-log purging effect. These purging procedures did not cause a loss of normal myeloid (granulocyte-macrophage colony-forming units, CFU-GM) or erythroid (erythroid burst-forming units, BFU-e) progenitors from the bone marrow. This study indicates that the combination of the two methods results in a highly efficient purging procedure for the removal of cALL+ cells from autologous bone marrow cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2298269

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  2 in total

1.  Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody.

Authors:  A Hekman; A Honselaar; W M Vuist; J J Sein; S Rodenhuis; W W ten Bokkel Huinink; R Somers; P Rümke; C J Melief
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Efficient B cell depletion via diphtheria toxin in CD19-Cre/iDTR mice.

Authors:  Filiz Demircik; Thorsten Buch; Ari Waisman
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.